GOLD REPORT 2023
WHAT'S NEW?
1
INITIAL TREATMENT
LAMA/LABA optimal first-line treatment option for symptomatic patients with COPD, regardless of exacerbation risk1*
LAMA/LABA/ICS should be considered for a few COPD patients at initiation of pharmacological treatment1,2*†
LABA/ICS use in COPD is not encouraged1‡
LEARN MORE
2
INHALER CHOICE
GOLD 2023 recommends matching the inhaler with each patient’s inhalation ability1
pMDIs and, to a lesser extent, SMIs require coordination and for patients to make a slow, deep inhalation1
DPIs are only appropriate if the patient can make a forceful, deep inhalation1
LEARN MORE
3
FOLLOW-UP TREATMENT
Escalation to LAMA/LABA in patients with persistent breathlessness on bronchodilator monotherapy1
Consider adding ICS if a patient continues to exacerbate on LAMA/LABA and eosinophils are ≥100 cells/μL1
No addition of ICS for persistent breathlessness, unless accompanied by exacerbations1
LEARN MORE
Footnotes & References >
PC-CRP-104007 - November 2022 Spiolto